Schedule 13D ownership disclosure

LANTERN PHARMA INC

Common Stock, par value $0.0001 per share · CUSIP: 51654W101

Event date: 2025-06-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOS FUND I, LPReported CIK 0001697316

    Shares: 323,335.00 · Class: 3.00%

  • BIOS FUND I QP, LPReported CIK 0001700297

    Shares: 189,117.00 · Class: 1.75%

  • BIOS FUND II, LPReported CIK 0001714576

    Shares: 114,272.00 · Class: 1.06%

  • BIOS FUND II QP, LPReported CIK 0001716869

    Shares: 373,178.00 · Class: 3.46%

  • BIOS FUND II NT, LPReported CIK 0001728851

    Shares: 49,957.00 · Class: 0.46%

  • BP DIRECTORS, LPReported CIK 0001813311

    Shares: 26,093.00 · Class: 0.24%

  • BIOS EQUITY PARTNERS, LPReported CIK 0001813314

    Shares: 538,545.00 · Class: 4.99%

  • BIOS EQUITY PARTNERS II, LPReported CIK 0001813313

    Shares: 537,407.00 · Class: 4.98%

  • CAVU MANAGEMENT, LPReported CIK 0001813270

    Shares: 1,075,952.00 · Class: 9.98%

  • BIOS CAPITAL MANAGEMENT, LPReported CIK 0001813845

    Shares: 1,075,952.00 · Class: 9.98%

  • CAVU ADVISORS, LLCReported CIK 0001813310

    Shares: 1,075,952.00 · Class: 9.98%

  • BIOS ADVISORS GP, LLCReported CIK 0001813844

    Shares: 1,075,952.00 · Class: 9.98%

  • LESLIE W. KREISReported CIK 0001813316

    Shares: 1,075,952.00 · Class: 9.98%

  • AARON G.L. FLETCHERReported CIK 0001789490

    Shares: 1,075,952.00 · Class: 9.98%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-059524
Form type
SCHEDULE 13D/A
Filer
Bios Equity Partners, LP
CIK
CIK 1813314
Filed
Jun 13, 2025
Reporting period
Jun 12, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub